Clinical Trials

Find a Clinical Trial

Clinical trials offer patients access to emerging treatments that are shaping the future of cancer care. Our clinical research program works alongside your care team to evaluate new therapies, improve how treatments are delivered and enhance quality of life during and after treatment.

If you are interested in participating in a clinical trial, ask your physician if you qualify.Ā  To make our clinical trials available to all CARTI patients, all of our physicians serve as sub-investigators; this means that your treating physician can enroll you onto a clinical trial if you are eligible.

Participation in research isĀ always voluntary.Ā For further information on clinical trials, please visitĀ http://www.clinicaltrials.gov.

If you have any additional questions for or about CARTI’s Research Team, please call 501.906.4199 or emailĀ Research@CARTI.com.Ā 

 

Dr. Kamal Patel, M.D.
carti logo
Principal Investigator: Dr. Kamal Patel, M.D.

MT GROUP

Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients

Dr. Ryan Hall, M.D.
carti logo
Principal Investigator: Dr. Ryan Hall, M.D.

CARIS

  • CARIS Fusion
  • CARIS 901
  • CARIS Matched 701

Dr. Ryan Hall, M.D.
carti logo
Principal Investigator: Dr. Ryan Hall, M.D.

RIVER-MPDAC; C3651021

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

ClinicalTrials.gov ID: NCT06989437

Dr. Sam Makhoul, M.D., FASCO
carti logo
Principal Investigator: Dr. Sam Makhoul, M.D., FASCO

NRG-CC012CD; SYMON

Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

ClinicalTrials.gov ID: NCT06279013

Dr. Andrew Briggler, M.D.
carti logo
Principal Investigator: Dr. Andrew Briggler, M.D.

PAN-TUMOR MRD STUDY; FH-PRWS-07-002

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

ClinicalTrials.gov ID: NCT06605404

Dr. David Hays, M.D., FACR
carti logo
Principal Investigator: Dr. David Hays, M.D., FACR

CYBRID-02 (BSK22-2562)

Observational basket trial to collect tissue to train and validate a live tumor diagnostic platform.

ClinicalTrials.gov ID: NCT05520099

Dr. David Kuperman, M.D.
carti logo
Principal Investigator: Dr. David Kuperman, M.D.

TROPION-SWISH; D926UL0001

An open-label, single-arm study of prophylaxis of Datopotamab deruxtecan (Dato-DXd) -related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

ClinicalTrials.gov ID: NCT07357597

Dr. Ryan Hall, M.D.
carti logo
Principal Investigator: Dr. Ryan Hall, M.D.

MERK MK2870-023

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Clinicaltrials.gov Number: NCT06422143

Dr. Sam Makhoul, M.D., FASCO
carti logo
Principal Investigator: Dr. Sam Makhoul, M.D., FASCO

ADJUVANT WIDER; CLEE011012011

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy In a Close-to Clinical Practice Patient Population With HR+ HER2āˆ’ Early Breast Cancer

Clinicaltrials.gov Number: NCT05827081

Dr. David Kuperman, M.D.
carti logo
Principal Investigator: Dr. David Kuperman, M.D.

FOURLIGHT-03; C4391024

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer who Have not Received any Prior Systemic Anticancer Treatment for Advanced/Metastatic Disease

Clinicaltrials.gov Number: NCT06760637